Amicus Therapeutics, Inc.
General ticker "FOLD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.4B (TTM average)
Amicus Therapeutics, Inc. follows the US Stock Market performance with the rate: 26.6%.
Estimated limits based on current volatility of 1.8%: low 9.63$, high 9.98$
Factors to consider:
- Total employees count: 499 as of 2024
- US accounted for 33.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Third-party risks, Regulatory and compliance, Market acceptance, Market competition, Intellectual property risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.61$, 14.31$]
- 2025-12-31 to 2026-12-31 estimated range: [7.74$, 14.59$]
Financial Metrics affecting the FOLD estimates:
- Positive: with PPE of 42.0 at the end of fiscal year the price was very low
- Positive: -3.60 < Operating profit margin, % of 4.71
- Negative: Operating cash flow per share per price, % of -1.15 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 1.69 <= 3.41
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term FOLD quotes
Long-term FOLD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $328.15MM | $396.77MM | $528.29MM |
| Operating Expenses | $540.27MM | $473.98MM | $503.42MM |
| Operating Income | $-212.12MM | $-77.21MM | $24.88MM |
| Non-Operating Income | $-29.92MM | $-72.89MM | $-53.63MM |
| Interest Expense | $37.12MM | $50.15MM | $49.60MM |
| R&D Expense | $276.68MM | $152.38MM | $109.36MM |
| Income(Loss) | $-242.04MM | $-150.10MM | $-28.76MM |
| Taxes | $-5.47MM | $1.48MM | $27.35MM |
| Profit(Loss)* | $-236.57MM | $-151.58MM | $-56.11MM |
| Stockholders Equity | $123.05MM | $160.17MM | $194.04MM |
| Inventory | $23.82MM | $59.70MM | $118.78MM |
| Assets | $724.17MM | $777.88MM | $785.03MM |
| Operating Cash Flow | $-166.57MM | $-69.09MM | $-33.89MM |
| Capital expenditure | $3.77MM | $7.44MM | $3.55MM |
| Investing Cash Flow | $92.32MM | $98.06MM | $-0.56MM |
| Financing Cash Flow | $-7.46MM | $61.68MM | $5.12MM |
| Earnings Per Share** | $-0.82 | $-0.51 | $-0.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.